BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24293993)

  • 1. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients.
    De Backer J; Vos W; Van Holsbeke C; Vinchurkar S; Claes R; Parizel PM; De Backer W
    Int J Chron Obstruct Pulmon Dis; 2013; 8():569-79. PubMed ID: 24293993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
    Tse HN; Tseng CZ
    Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
    Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
    Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study.
    Stav D; Raz M
    Chest; 2009 Aug; 136(2):381-386. PubMed ID: 19447919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
    De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
    Tse HN; Raiteri L; Wong KY; Yee KS; Ng LY; Wai KY; Loo CK; Chan MH
    Chest; 2013 Jul; 144(1):106-118. PubMed ID: 23348146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
    Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
    COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
    Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidation pathway and exacerbations in COPD: the role of NAC.
    Matera MG; Calzetta L; Cazzola M
    Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
    van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
    J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acute effect of budesonide/formoterol in COPD: a multi-slice computed tomography and lung function study.
    De Backer LA; Vos W; De Backer J; Van Holsbeke C; Vinchurkar S; De Backer W
    Eur Respir J; 2012 Aug; 40(2):298-305. PubMed ID: 22183484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, physiological, and radiological features of asthma-chronic obstructive pulmonary disease overlap syndrome.
    Suzuki T; Tada Y; Kawata N; Matsuura Y; Ikari J; Kasahara Y; Tatsumi K
    Int J Chron Obstruct Pulmon Dis; 2015; 10():947-54. PubMed ID: 26028967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
    Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
    Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
    De Backer W; De Backer J; Verlinden I; Leemans G; Van Holsbeke C; Mignot B; Jenkins M; Griffis D; Ivanov S; Fitzpatrick J; St Rose E; Martin UJ; Reisner C
    Ther Adv Respir Dis; 2020; 14():1753466620916990. PubMed ID: 32380894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China.
    Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P
    Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
    Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
    Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.
    Calzetta L; Rogliani P; Facciolo F; Rinaldi B; Cazzola M; Matera MG
    Biomed Pharmacother; 2018 Jul; 103():1-8. PubMed ID: 29635121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
    Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
    Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral
    Hirai DM; Jones JH; Zelt JT; da Silva ML; Bentley RF; Edgett BA; Gurd BJ; Tschakovsky ME; O'Donnell DE; Neder JA
    J Appl Physiol (1985); 2017 May; 122(5):1351-1361. PubMed ID: 28255088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD.
    De Backer LA; Vos WG; Salgado R; De Backer JW; Devolder A; Verhulst SL; Claes R; Germonpré PR; De Backer WA
    Int J Chron Obstruct Pulmon Dis; 2011; 6():637-46. PubMed ID: 22162649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.